Invion is a life sciences company focussed on the development of treatments for major opportunities in chronic inflammatory and autoimmune diseases. Invion is an ASX listed company (ASX:IVX), with operations in Melbourne, Australia and Delaware, USA.


Exclusive Distribution and Licence Agreement: Invion has been appointed exclusive distributor and licensee in Australia and New Zealand of Photosoft for the treatment of cancers. The appointment has been made by The Cho Group, a Hong Kong based group that funded and successfully commercialised a number of unique and advanced technologies.

R&D Services Agreement: Invion will conduct clinical development of Photosoftglobally, initially targeting prostate cancer in Australian-run clinical trials. The Cho Group will provide non-dilutive funding for the clinical trials. The clinical development program is being designed and managed by a joint steering committee between the two companies.

Read more in the latest corporate presentation.